HER2过表达与胃癌预后及靶向治疗的关系  

Overexpression of HER2 in Gastric Cancer and Its Relation to Prognosis and Target Therapy

作　　者：李保奇[1] 岑洪[1] 胡晓桦[1] 

机构地区：[1]广西医科大学附属肿瘤医院化疗三科,南宁530021

出　　处：《医学综述》2010年第9期1321-1323,共3页Medical Recapitulate

摘　　要：晚期胃癌预后差,化疗效果不佳。人类表皮生长因子受体2(HER2)从多个途径影响肿瘤细胞的生物活动,导致肿瘤的复发和转移。胃癌肠型比弥漫型HER2阳性表达率高,胃食管连接部HER2阳性表达率比胃部的高。Hercep Test评分标准可用于评估HER2表达水平。最近研究发现,部分胃癌患者存在HER2过表达是预后不良因素。曲妥珠单抗联合化疗有可能是未来治疗HER2过表达胃癌的标准方案。The patients with advanced gastric cancer have poor prognosis and poor response to chemotherapy.The HER2 protein（p185,HER2/neu,ErbB-2）is a member of the epidermal growth factor receptors（EGFRs）,which acts as an oncogene.GEJ cancers exhibited higher rates of HER2 amplification than did gastric tumors.HER2 expression is more common in Intestinal-type cancers than in diffuse-type cancers.Hercep Test score criteria can be applied to assess the levels of HER2 expression.Overexpression of HER2 protein in gastric cancer was a poor prognostic factor described in recent years.The combination of trastuzumab and chemotherapy may become a new standard therapy for HER2 positive gastric cancer.

关 键 词：胃癌 人类表皮生长因子受体2 预后 靶向治疗 

分 类 号：R735[医药卫生—肿瘤]